NCI-H1993 Xenograft Model Service for NSCLC

The NCI-H1993 xenograft model represents a robust MET-amplified lung adenocarcinoma platform distinguished by LKB1-mutant tumor biology and exceptional sensitivity to MET-directed inhibitors, offering a clinically relevant substrate for evaluating targeted therapies and glucocorticoid-mediated combination strategies in NSCLC. Alfa Cytology leverages this authenticated MET-driven cell line—paired with rigorous cell banking, optimized implantation protocols, and comprehensive endpoint analysis—to advance your preclinical programs with reproducible, publication-ready pharmacodynamic data.

Overview of NCI-H1993 Xenograft Model for NSCLC

The NCI-H1993 cell line was established in 1986 by A.F. Gazdar and J.D. Minna at the National Cancer Institute from metastatic cells obtained from a lymph node of a 47-year-old Caucasian female smoker (30 pack-years) diagnosed with stage 3A lung adenocarcinoma. This line is molecularly defined by MET (c-Met) gene amplification and constitutive overexpression, which drives hepatocyte growth factor (HGF)-independent receptor activation and downstream PI3K/AKT and MAPK/ERK signaling hyperactivation. Additionally, NCI-H1993 harbors a homozygous TP53 mutation (p.Cys242Trp, c.726C>G) and an STK11/LKB1 inactivating mutation, the latter conferring a unique therapeutic vulnerability to glucocorticoid receptor (GR) agonists such as dexamethasone via induction of the cyclin-dependent kinase inhibitor CDKN1C/p57(Kip2). Both KRAS and EGFR remain wild-type, positioning NCI-H1993 as a pure MET-driven model without confounding canonical oncogene mutations.

Fig 1. NCI-H1993 was identified as a dexamethasone-sensitive LKB1-mutant NSCLC line with high CPS1 expression, showing DEX-induced p57(Kip2) upregulation, G1 cell-cycle arrest, senescence-like morphology and ATP elevation, validated as the responder cell line xenograft model. (Huffman, Kenneth E., et al., 2023)

In immunodeficient hosts, NCI-H1993 demonstrates reliable tumorigenicity with robust engraftment when 1×10⁶ to 5×10⁶ cells are implanted subcutaneously with Matrigel support. Tumors become palpable within 7–10 days and progress with consistent kinetics. Preclinical validation has demonstrated profound sensitivity to MET inhibitors including crizotinib and tepotinib, with treated tumors showing marked downregulation of phosphorylated MET (p-MET) and its downstream effectors p-AKT and p-ERK. The model also exhibits glucocorticoid-mediated G1/S cell cycle arrest in vivo, with dexamethasone monotherapy showing efficacy comparable to cisplatin and additive benefit when combined with platinum agents. These dual vulnerabilities—MET amplification and LKB1-mutant glucocorticoid sensitivity—render the NCI-H1993 xenograft a versatile tool for evaluating MET-targeted monotherapy, combination regimens, and novel precision medicine approaches in a molecularly defined lung adenocarcinoma context.

Cell Line Information: NCI-H1993

The table below consolidates the essential biological, genetic, and operational characteristics of the NCI-H1993 cell line to support informed experimental design and data interpretation.

Our Services

Alfa Cytology delivers a comprehensive NCI-H1993 xenograft program encompassing authenticated cell banking, mycoplasma and sterility verification, tumor implantation, longitudinal monitoring, and multi-modal endpoint analysis. Our standardized workflows—refined across numerous receptor tyrosine kinase-driven and LKB1-mutant lung cancer studies—ensure consistent engraftment, reproducible tumor growth curves, and pharmacologically meaningful readouts that strengthen your preclinical development decisions.

Workflow of NCI-H1993 Xenograft Model Construction

Construction of the NCI-H1993 xenograft model at Alfa Cytology follows a regimented, IACUC-approved pipeline that prioritizes genetic authenticity, sterile technique, and reproducible tumor growth. Each operational phase is documented under GLP-aligned quality systems to ensure complete auditability from cell thaw to final dataset delivery.

1. Master Cell Bank Revival & Expansion: NCI-H1993 cells are revived from authenticated, low-passage master stocks stored under liquid nitrogen and expanded in RPMI-1640 supplemented with 10% FBS. Each batch undergoes mycoplasma PCR screening, STR profiling confirmation against the published ATCC profile, and viability assessment prior to harvest.
2. Pre-Implantation Cell Preparation: Cultures in logarithmic growth phase are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 200×g for 5 minutes. The pellet is washed twice with sterile PBS to eliminate serum traces, then resuspended in ice-cold PBS or HBSS at a concentration of 5×10⁷ cells/mL for a final inoculum of 5×10⁶ cells per 100 μL injection volume.
3. Matrigel Mixing & Injection Preparation: High-concentration, phenol-red-free Matrigel is thawed at 4°C overnight and maintained on ice. The cell suspension is mixed 1:1 with cold Matrigel immediately before injection to promote cell retention, angiogenesis, and standardized engraftment kinetics. The mixture is kept on ice at all times to prevent premature polymerization.
4. Subcutaneous Tumor Implantation: Six- to eight-week-old female SCID or NOD/SCID mice are acclimatized for a minimum of seven days. Under aseptic conditions, 100–200 μL of the cell-Matrigel suspension is injected subcutaneously into the right flank using a 26-gauge needle. Mice are monitored daily for general health and injection-site integrity.
5. Tumor Establishment & Cohort Randomization: Tumors are monitored by palpation beginning on day 5 post-implantation. Once tumors become palpable and reach a mean volume of 80–120 mm³—typically 7–10 days after injection—mice are stratified by tumor size and randomized into vehicle control and treatment cohorts (n = 8–10 per group).
6. Dosing, Monitoring & Endpoint Analysis: Test agents are administered according to protocol-specified routes (PO, IP, IV, or SC) and schedules. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Studies conclude at a humane endpoint (typically 2,000 mm³ or 21–28 days post-treatment), at which point tumors are excised, weighed, and allocated for histopathology (H&E), immunohistochemistry (p-MET, p-AKT, p-ERK, Ki-67, CD31, TUNEL), and molecular profiling (qPCR, Western blot, RNA-seq). Serum is collected for pharmacokinetic correlation where applicable.

Fig 2. NCI-H1993 xenograft model construction workflow.

Case Study

In a recent preclinical evaluation, Alfa Cytology established the NCI-H1993 subcutaneous xenograft to assess the anti-tumor efficacy of a novel MET-selective tyrosine kinase inhibitor in a MET-amplified, LKB1-mutant lung adenocarcinoma context. Following robust tumor engraftment in female SCID mice, animals were randomized into vehicle control and treatment arms (n = 8–10 per group) once mean tumor volume reached approximately 100 mm³. The test compound was administered via oral gavage on a once-daily schedule for 21 days at two escalating dose levels alongside a tepotinib reference arm. Longitudinal monitoring revealed dose-dependent tumor growth inhibition in treated animals relative to vehicle controls, with the highest dose cohort demonstrating sustained suppression throughout the treatment window. At study termination, harvested tumors underwent comprehensive histopathological review and biomarker analysis, including p-MET and p-AKT immunostaining to confirm target engagement and downstream pathway modulation, Ki-67 quantification to evaluate proliferative inhibition, and TUNEL assay to assess apoptotic induction. Body weight records remained stable across all cohorts, indicating an acceptable tolerability profile. Complete pharmacodynamic datasets, including individual tumor growth trajectories and immunohistochemistry images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H1993 xenograft program provides access to a purpose-built infrastructure optimized for MET-driven and LKB1-mutant lung cancer preclinical research. Our service architecture combines scientific depth with operational agility to accelerate your compound evaluation timeline.

• Authenticated NCI-H1993 master and working cell banks are maintained under liquid nitrogen with biannual STR confirmation against the ATCC reference profile and documented mycoplasma negativity, ensuring genetic stability across every study.
• Standardized implantation protocols with Matrigel support yield consistent tumor engraftment and predictable growth kinetics in this MET-amplified adenocarcinoma model, enabling precise power calculations and efficient cohort sizing.
• Flexible study architectures accommodate single-agent MET inhibitor, MET-targeted ADC, glucocorticoid combination, and dose-escalation designs, with dosing routes and schedules tailored to your compound properties.
• On-site histopathology and IHC capabilities—including p-MET, p-AKT, p-ERK, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor coordination or sample custody interruptions.
• Secure client data portals provide real-time visibility into tumor measurements, body weights, and study milestones, with automated notifications at predefined protocol checkpoints.
• Each engagement is supported by a dedicated scientific project manager who coordinates weekly progress reports, interim data presentations, and adaptive protocol amendments aligned with your evolving research priorities.

Contact Us

If your research pipeline targets the MET-amplified NSCLC landscape—whether advancing a next-generation MET inhibitor, exploring glucocorticoid-mediated combination strategies in LKB1-mutant tumors, or evaluating MET-targeted ADCs in a wild-type EGFR and KRAS context—Alfa Cytology offers the NCI-H1993 xenograft expertise to advance your preclinical objectives with scientific rigor. Reach out to our scientific team today to discuss your study parameters, request a customized proposal, or arrange a consultation with our oncology model specialists. We are committed to converting your therapeutic hypothesis into robust, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.